|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found that performing BRAF(V600E) mutation analysis on the fine-needle aspiration biopsy specimens was of great help to make a therapeutic decision for thyroid nodules when the fine-needle aspiration biopsy results were equivocal.
|
21239517 |
2011 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
The probability of PTC for thyroid nodules with intermediat</span>e-risk (IR) US and atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) FNAB was significantly dependent on BRAF V600E mutation status based on our prediction table (negative, 29.2% vs positive, 87.5%; P < 0.001).
|
26020381 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (FNAB) specimens in order to assess FNAB's usefulness in preoperative papillary thyroid carcinoma (PTC) diagnosis with the contemporaneous analysis of RET/PTC1 and RET/PTC3 rearrangements obtained from ex vivo thyroid nodules.
|
17727338 |
2007 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Follow-up BRAF(V600E) mutation analysis may be helpful in the diagnosis of selected thyroid nodules negative for BRAF(V600E) mutation on initial analysis, which are assessed as suspicious malignant on US, diagnosed as non-diagnostic, benign or atypia on follow-up US-FNA.
|
23505540 |
2013 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
|
23476074 |
2013 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
The molecular tests on the thyroid nodule revealed the presence of BRAF-V600E mutation, but wild type BRAF in the ectopic tissue.
|
23200790 |
2013 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Initial clinical experience with BRAF(V600E) mutation analysis of core-needle biopsy specimens from thyroid nodules.
|
26215382 |
2016 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Diagnostic value of B-RAF(V600E) in difficult-to-diagnose thyroid nodules using fine-needle aspiration: systematic review and meta-analysis.
|
24167125 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
The application of BRAF(V600E) mutation analysis in FNA specimens is more effective for thyroid nodules with malignant US features as compared with nodules without malignant US features.
|
20187782 |
2010 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
One hundred and fifty-three thyroid samples obtained by FNA of thyroid nodules from 151 patients were subjected to the analysis of BRAF V600E mutation by direct sequencing.
|
25194426 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients.
|
23280049 |
2013 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules.
|
26597052 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Of the 56 previous AUS result thyroid nodules with surgical management, BRAF(V600E) mu</span>tation analysis led to therapeutic surgery in 5.4% by decreasing unnecessary diagnostic surgery.
|
25978151 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evaluation of the Anyplex BRAF V600E real-time detection assay using dual-priming oligonucleotide technology in fine-needle aspirates of thyroid nodules.
|
26354351 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
For thyroid nodules that were diagnosed cytologically as suspicious for papillary thyroid cancer, univariate pooled sensitivity using FNA and BRAF(V600E) results was 52% (95% confidence interval, 39%-64%).
|
26232865 |
2015 |